Clinical trials: Lung Tumors
Non Small Cell Lung Cancer
Detection of Circulating Biomarkers of Immunogenic Cell Death
In this exploratory study, the investigators will investigate if markers (molecular and immunological) of ICD or anti-tumor immunity (exosomal or molecular) can be detected in the serum of patients after high-dose radiotherapy…
- Trial name
- ICD (NCT02921854)
- Testing
- Blood withdrawal
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 60 people
- Sponsor
- Maastricht Radiation Oncology
Non-Small Cell Lung Cancer
A Study of ABT-751 in Patients With Non-Small Cell Lung Cancer
The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with non-small cell lung cancer.
- Trial name
- NCT00073151
- Testing
- ABT-751
- Where
- 17 sites in United States
- Volunteers
- 30 people
- Sponsor
- Abbott
Non Small Cell Lung Cancer (NSCLC)
Osimertinib Study in Indian Patients
This is a prospective, single-arm, multicenter, phase-IV study investigating the safety of osimertinib in Indian adult patients.
- Trial name
- NCT03853551
- Testing
- Osimertinib
- Where
- 7 sites in India
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Large Cell Neuroendocrine Carcinoma of the Lung
A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung
This phase II clinical trial evaluates the efficacy, safety and tolerability of Obrixtamig in addition to standard of care chemotherapy (Platinum/Etoposide) in LCNEC.
- Trial name
- ALPINE 2 (NCT07561645)
- Testing
- Obrixtamig
- Volunteers
- 75 people
- Sponsor
- Technische Universität Dresden
Neoplasm of Lung, Thoracic Surgery, Video-Assisted
Efficacy of Continous Regional Anesthesia Using m. Erector Spinae Catheter After VATS Procedures
Investigators will analyze the efficacy of continuous regional anesthesia through a catheter under erector spinae muscle in a prospective, randomized, double blind, placebo-controlled study.
- Trial name
- NCT04062045
- Testing
- Ropivacaine Hcl 0.2% Inj Vil 10Ml, Saline 0.9%
- Where
- Slovenia
- Volunteers
- 50 people
- Sponsor
- Surgery Bitenc
Lung Cancer
Study of Proteins in Tumor Samples From Patients With Non-Small Cell Lung Cancer
This research studies protein in tumor samples from patients with non-small cell lung cancer. Finding specific proteins in tumor tissue samples from patients with cancer may help doctors tell what type of lung cancer a patient…
- Trial name
- NCT01415739
- Testing
- laboratory biomarker analysis
- Where
- United States
- Sponsor
- Alliance for Clinical Trials in Oncology
Safety Issues
Phase 1 Study of Oral RH324 in Advanced Non-Small Cell Lung Cancer
Phase 1 open label dose ranging study of RH324 in advanced non-small cell lung cancer
- Trial name
- NCT05580172
- Testing
- RH324
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- ReHeva Biosciences,Inc.
NSCLC Stage IV, Chemotherapy Effect
EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide
EGFR-TKIs are the standard first-line treatment option for EGFR-mutant NSCLC. After a randomized phase II trial, JO25567 was presented at 2014 ASCO, the synergistic effect of progression-free survival(PFS) could be expected when…
- Trial name
- NCT03341494
- Testing
- Thalidomide
- Where
- 2 sites in China
- Volunteers
- 128 people
- Sponsor
- Fujian Cancer Hospital
NSCLC, Stage III
Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy
This is a randomized, open-label, multicenter, phase II trial investigating the combination of thoracic radiotherapy plus Durvalumab in patients with locally advanced, unresectable NSCLC (stage III) that are unfit for…
- Trial name
- TRADE-hypo (NCT04351256)
- Testing
- Durvalumab Injection [Imfinzi], Thoracic Radiotherapy (TRT) conventionally, Thoracic Radiotherapy (TRT) hypofractionated
- Where
- 14 sites in Germany
- Volunteers
- 51 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Lung Cancer, Non-Small Cell, Neoplasms
Molecular Disease Characterization Initiative (MDCI)
This is a single arm interventional molecular analysis study with no administration of investigational product and no masking. This multicenter study will involve participants with advanced/metastatic disease for the purpose of…
- Trial name
- NCT04772053
- Testing
- Tumor biopsy
- Where
- 2 sites in United States, Spain
- Volunteers
- 6 people
- Sponsor
- GlaxoSmithKline
Thymus Tumors, Adoptive Cellular Therapy
Rapid Autopsy and Procurement of Cancer Tissue
Background: Individuals with cancer of the lung, chest cavity, ovary, or bladder, as well as patients who have been treated with adoptive cell therapy unfortunately commonly succumb to their disease.
- Conditions
- Thymus Tumors, Adoptive Cellular Therapy, Mesothelioma, Genitourinary Cancers
- Trial name
- NCT01851395
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small-Cell Lung Cancer
EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism
BIM deletion polymorphism might be associated with a poor clinical response to EGFR-TKIs in patients who had NSCLC with EGFR mutations.
- Trial name
- NCT02859077
- Testing
- EGFR-TKI, Chemotherapy（pemetrexed/gemcitabine）, Chemotherapy（carboplatin）
- Volunteers
- 100 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Non Small Cell Lung Cancer, Lung Nodule
Evaluation of a Pneumotachograph (SPI) for the Production of PET and CT Acquisitions Synchronized With Breath for the Assessment of Extension of Lung Cancer
This is a pilot study, single-center, prospective, open-label, to assess the acceptability and performance of the experimental medical device (SPI) used during an imaging examination (PET / CT 4D imaging in synchronized mode…
- Trial name
- SPI COHERENCE (NCT01720186)
- Testing
- PET/CT 4D imaging in a synchronized mode centered on the thorax.
- Where
- France
- Volunteers
- 46 people
- Sponsor
- Institut Claudius Regaud
NSCLC
Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
This is a Phase 2, open-label, multicenter study to evaluate the efficacy and the safety/tolerability of poziotinib in two patient cohorts for up to 114 previously treated NSCLC patients with any systemic therapy (57 patients…
- Trial name
- NCT04044170
- Testing
- Poziotinib
- Where
- 26 sites in China, South Korea
- Volunteers
- 5 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Primary Solid Tumors
Robotic Surgery in Pulmonary Metastasectomy
The study is observational, multicenter retrospective and will involve multiple research centers. The aim is to outline the indications for surgical management with robot-assisted pulmonary metastasectomy through a confrontation…
- Trial name
- ROME (NCT06466070)
- Where
- 3 sites in Italy
- Volunteers
- 1,650 people
- Sponsor
- Scientific Institute San Raffaele
Lung Adenocarcinoma
Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm
This study aims to evaluate the non-inferiority in recurrence-free survival and overall survival of segmentectomy compared with lobectomy in patients with lung adenocarcinoma ≤ 2 cm with micropapillary and solid subtype negative…
- Trial name
- NCT04937283
- Testing
- Segmentectomy, Lobectomy
- Where
- 14 sites in China
- Volunteers
- 690 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Carcinoma, Non-Small-Cell Lung
KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) in combination with MK-4830 in treatment-naïve participants with advanced squamous or non-squamous NSCLC that is PD-L1 positive.
- Trial name
- NCT04165083
- Testing
- Pembrolizumab, MK-4830, MK-0482
- Where
- 39 sites in United States, Hungary and 5 more
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
HRD Cancer, SCLC
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
Background: Small cell lung cancer and PARP inhibitor resistant tumors are aggressive cancers. Current treatments for people with these tumors yield little benefit. Researchers want to see if a combination of drugs can help.
- Conditions
- HRD Cancer, SCLC, Advanced Solid Tumors
- Trial name
- NCT04826341
- Testing
- Berzosertib, Sacituzumab Govitecan
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer Stage I, Lung Cancer Stage II
Calypso Guided High Precision Stereotactic Ablative Radiosurgery for Lung TUmours Using Real-Time Tumour Tracking & Respiratory Gating
This is a single arm seamless phase I/II prospective cohort study. Patients with early stage Non-Small Cell Lung Cancer (T1-T2N0M0) or those with a single pulmonary metastasis of a known malignancy (either following radical…
- Conditions
- Lung Cancer Stage I, Lung Cancer Stage II, Lung Cancer, Nonsmall Cell, Lung Cancer Recurrent
- Trial name
- GPS (NCT03322072)
- Testing
- Real-Time Position Transponder Beacons
- Where
- 2 sites in Canada
- Volunteers
- 28 people
- Sponsor
- CancerCare Manitoba
Non-Small Cell Lung Cancer
Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada
This study uses existing medical records to better understand how immunotherapy is used in people in Europe and Canada with non-small cell lung cancer (NSCLC) who undergo surgery.
- Trial name
- NCT07718139
- Testing
- nivolumab, pembrolizumab, durvalumab
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.